Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Models estimating recurrence-free survival (RFS) after hepatectomy for hepatocellular carcinoma (HCC) rely on clinical variables and often overlook tumor immunobiology. The Liver Immune Status Index (LISI), derived from BMI, albumin, and Fibrosis-4 (FIB-4), reflects liver-resident natural killer (NK) cell activity. We validated the HISCO-HCC score, combining LISI, tumor burden score (TBS), and alpha-fetoprotein (AFP), using an international cohort.
Methods: Patients undergoing curative-intent hepatectomy for HCC (2000-2023) were identified from an international database (median follow-up: 38.9 [14.9-67.5] months). RFS was the primary endpoint. LISI's predictive performance was compared with other liver-related indices. The original HISCO-HCC (oHISCO-HCC) was recalibrated via multivariable Cox regression in a training cohort (80 %) stratified by region, yielding a modified score (mHISCO-HCC). Validation was conducted in the testing cohort (20 %).
Results: Among 1213 patients, LISI had the highest AUCs among liver-related indices for 1-/2-year RFS (0.60/0.60) and 1-/5-year OS (0.64/0.60). The formula: mHISCO-HCC = 0.49 × TBS + 0.41 × log(AFP) + 0.13 × LISI. In testing, mHISCO-HCC outperformed oHISCO-HCC and mHALT-HCC for 12-/36-/60-month RFS (AUCs: 0.73/0.71/0.66) with the lowest AIC. It also had the highest OS AUCs and stratified RFS and OS (p < 0.001).
Conclusions: The mHISCO-HCC score, integrating tumor morphology, biology, and NK cell-based immunity, improves prediction of recurrence and survival. It may aid postoperative stratification.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hpb.2025.06.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Triple-Negative Breast Cancer Presenting as Recurrent Cystic Lesions During Lactation: A Case Report.
Clin Case Rep
September 2025
Department of Thoracic Surgery, Fu Xing Hospital, the Eighth Clinical Medical College Capital Medical University Beijing China.
Lactation-associated breast cancer poses diagnostic challenges due to physiological breast changes that may mask malignancies. Triple-negative breast cancer (TNBC) during lactation is rare and aggressive, requiring vigilant evaluation and treatment. This report highlights the diagnostic dilemma of recurrent cystic breast lesions during lactation, which can mimic benign conditions like galactoceles but may conceal aggressive TNBC, leading to potential delays in diagnosis despite initial conservative approaches such as aspiration.
View Article and Find Full Text PDFPreoperative embolization improves local control and modulates gene expression in atypical WHO grade 2 meningioma.
Neuro Oncol
September 2025
Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Background: Preoperative embolization is hypothesized to reduce blood loss and operative time for meningioma resection, but the impact of preoperative embolization on long-term oncological outcomes and molecular features of meningiomas is incompletely understood. Here we investigate how preoperative embolization influences perioperative and long-term outcomes and molecular features of atypical WHO grade 2 meningiomas.
Methods: Patients who underwent resection of WHO grade 2 meningiomas from 1997 to 2021 were retrospectively identified from an institutional database.
Improving oncological outcomes for pelvic bone sarcomas: Is it possible?
Eur J Surg Oncol
August 2025
Royal Orthopaedic Hospital, Birmingham, United Kingdom.
Introduction: Pelvic bone sarcomas are rare, heterogeneous malignancies that present significant diagnostic and therapeutic challenges. Despite advances in imaging, surgical navigation, and multidisciplinary care, it remains unclear whether these innovations have improved outcomes across all histiotypes.
Material And Methods: We conducted a retrospective cohort study of 475 patients surgically treated for primary pelvic bone sarcomas between 2003 and 2022.
Revisiting the paradigm: Asymptomatic high-grade endometrial cancer diagnosis is not associated with improved outcomes.
Eur J Surg Oncol
September 2025
Barzilai University Medical Center, Ashkelon, Israel; Faculty of Health Sciences, Ben-Gurion University of Negev, Beer-Sheva, Israel.
Objective: To compare the survival of women with high grade endometrial cancer between asymptomatic and women presenting bleeding symptoms.
Design: An Israel Gynecologic Oncology Group multi-center retrospective cohort study.
Methods: The study included women who underwent surgery for high-grade endometrial cancer.
Revisiting BCG: The potential of rescue BCG therapy for BCG-unresponsive non-muscle-invasive bladder cancer.
Urol Oncol
September 2025
Department of Urology, Columbia University Irving Medical Center, New York, NY.
Objective: To evaluate the role of Rescue BCG in the treatment of BCG-unresponsive nonmuscle-invasive bladder cancer (NMIBC), in order to inform clinical decision-making especially when access to alternative therapies is limited.
Methods: From an institutional database, patients who met the criteria of BCG-unresponsive NMIBC between 2002 and 2023 were identified and sorted into 2 cohorts: those who received additional BCG therapy immediately after BCG-unresponsive designation and those who received alternative treatments such as intravesical chemotherapy and radical cystectomy. Primary endpoint was progression-free survival (PFS).